Article
Oncology
Cedric Pobel, Edouard Auclin, Diego Teyssonneau, Brigitte Laguerre, Mathilde Cancel, Elouen Boughalem, Johanna Noel, Pierre Emmanuel Brachet, Denis Maillet, Philippe Barthelemy, Carole Helissey, Constance Thibault, Stephane Oudard
Summary: Cabazitaxel multiple rechallenges can be a treatment option in heavily pretreated patients with metastatic castration-resistant prostate cancer, with efficacy and manageable toxicity for those who had a good initial response to cabazitaxel.
Article
Urology & Nephrology
Giulia Baciarello, Remy Delva, Gwenaelle Gravis, Youssef Tazi, Philippe Beuzeboc, Marine Gross-Goupil, Emmanuelle Bompas, Florence Joly, Charlotte Greilsamer, Thierry Nguyen Tan Hon, Philippe Barthelemy, Stephane Culine, Jean Francois Berdah, Mathilde Deblock, Raffaele Ratta, Aude Flechon, Caroline Cheneau, Aline Maillard, Geraldine Martineau, Isabelle Borget, Karim Fizazi
Summary: The preference for cabazitaxel over docetaxel among chemotherapy-naive men with mCRPC is mainly driven by reduced fatigue and improved quality of life.
Article
Oncology
Judith Passildas-Jahanmohan, Jean-Christophe Eymard, Melanie Pouget, Fabrice Kwiatkowski, Isabelle Van Praagh, Laurent Savareux, Marc Atger, Xavier Durando, Catherine Abrial, Damien Richard, Angeline Ginzac Couve, Emilie Thivat, Brigitte Monange, Philippe Chollet, Hakim Mahammedi
Summary: Despite good compliance and verified absorption of curcumin, the study showed no significant difference in progression-free survival between the curcumin and placebo groups, as well as in the secondary endpoints such as PSA response rate, overall survival, and quality of life. Consequently, the study was discontinued due to lack of efficacy.
Article
Urology & Nephrology
Masaki Shiota, Leandro Blas, Satoshi Kobayashi, Takashi Matsumoto, Eiji Kashiwagi, Ario Takeuchi, Junichi Inokuchi, Ken-ichiro Shiga, Akira Yokomizo, Masatoshi Eto
Summary: The study found that compared to docetaxel, first-line therapy with androgen receptor pathway inhibitors is associated with a better prognosis for metastatic castration-resistant prostate cancer patients. Pretreatment prostate-specific antigen levels and time to castration-resistant prostate cancer are differentially associated with progression-free survival and overall survival between the two treatment options.
INTERNATIONAL JOURNAL OF UROLOGY
(2022)
Article
Oncology
Nanwei Xu, Jinge Zhao, Fengnian Zhao, Haoyang Liu, Wenlian Yin, Sha Zhu, Ling Nie, Guangxi Sun, Linmao Zheng, Zhenhua Liu, Diming Cai, Junru Chen, Jindong Dai, Yuchao Ni, Zhipeng Wang, Xingming Zhang, Jiayu Liang, Yuntian Chen, Xu Hu, Xiuyi Pan, Xiaoxue Yin, Xudong Zhu, Yaowen Zhang, Zilin Wang, Yuhao Zeng, Minghao Wang, Pengfei Shen, Ni Chen, Hao Zeng
Summary: This study aimed to explore the predictive value of neuroendocrine differentiation (NED) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving abiraterone or docetaxel as first-line therapy. The results showed that NED was associated with shorter survival in both abiraterone and docetaxel treatment, suggesting that NED detection may help predict treatment outcomes and optimize treatment decisions for mCRPC patients.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Medicine, General & Internal
Mallika Marar, Qi Long, Ronac Mamtani, Vivek Narayan, Neha Vapiwala, Ravi B. Parikh
Summary: This study investigated the differences in outcomes between African American and non-Hispanic White men with metastatic castration-resistant prostate cancer (mCRPC) who received first-line abiraterone therapy. The results showed that African American men had a higher overall survival when receiving first-line abiraterone compared to non-Hispanic White men. However, there was a difference in outcomes between the two groups for first-line enzalutamide treatment.
Article
Urology & Nephrology
David Lorente, Casilda Llacer, Rebeca Lozano, Guillermo de Velasco, Nuria Romero-Laorden, Miguel Rodrigo, Angel Sanchez-Iglesias, Carlos di Capua, Elena Castro, Carlos Ferrer, Alfredo Sanchez-Hernandez, David Olmos
Summary: This study validated the prognostic value of the Armstrong risk model in patients treated with first-line androgen receptor signaling inhibitors, showing that low-risk patients received the greatest benefit. Further research is needed to establish the role of Armstrong risk groups for treatment selection in mCRPC patients.
Article
Urology & Nephrology
Ravi A. Madan, Fatima H. Karzai, Munjid Al Harthy, Daniel P. Petrylak, Joseph W. Kim, Philip M. Arlen, Inger Rosner, Marc R. Theoret, Lisa Cordes, Marijo Bilusic, Cody J. Peer, Nancy A. Dawson, Anna Couvillon, Amy Hankin, Moniquea Williams, Guin Chun, Helen Owens, Jennifer L. Marte, Min-Jung Lee, Yusuke Tomita, Akira Yuno, Jane B. Trepel, Sunmin Lee, Seth M. Steinberg, James L. Gulley, William D. Figg, William L. Dahut
Summary: The study evaluated the safety and efficacy of cabozantinib combined with docetaxel in mCRPC patients. Cabozantinib was found to be safely added to docetaxel treatment with potential enhanced efficacy. However, due to limited patient accrual, the phase 2 study was terminated early.
Article
Oncology
Orazio Caffo, Cinzia Ortega, Franco Nole, Donatello Gasparro, Claudia Mucciarini, Michele Aieta, Vittorina Zagonel, Roberto Iacovelli, Ugo De Giorgi, Gaetano Facchini, Antonello Veccia, Erica Palesandro, Elena Verri, Sebastiano Buti, Giorgia Razzini, Giovanni Bozza, Marco Maruzzo, Chiara Ciccarese, Giuseppe Schepisi, Sabrina Rossetti, Francesca Maines, Stefania Kinspergher, Lucia Fratino, Paola Ermacora, Maurizio Nicodemo, Monica Giordano, Donata Sartori, Daniela Scapoli, Roberto Sabbatini, Giovanni Lo Re, Franco Morelli, Alessandro D'Angelo, Isabella Vittimberga, Paolo Lippe, Francesco Carrozza, Caterina Messina, Luca Galli, Francesca Valcamonico, Camillo Porta, Giovanni Pappagallo, Massimo Aglietta
Summary: The combination of enzalutamide and docetaxel appears to be more clinically beneficial than docetaxel alone in previously untreated mCRPC patients, although serious adverse events were more frequent. The results suggest that first-line treatment with this combination could lead to additional clinical benefit when prompt and prolonged disease control is needed. However, caution should be exercised due to the study's phase II design and the lack of overall survival benefit.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Chemistry, Medicinal
Yujie Huang, You Zhai, Meijia Wu, Chengdong Chang, Jindan Luo, Dongsheng Hong, Qingwei Zhao, Yao Dai, Jian Liu
Summary: This study investigated the role of mTORC2 signaling in docetaxel-resistant prostate cells to find potential methods for clinical treatment. The expression of mTORC2 is crucial for docetaxel drug resistance in prostate cells. The mTORC1/2 inhibitor AZD8055 disrupts mTORC2 kinase activity more significantly than the mTORC1 inhibitor Rapamycin, leading to decreased docetaxel-mediated resistance. Therefore, reversing docetaxel resistance may become a therapeutic option for the treatment of metastatic castration-resistant prostate cancer patients.
DRUG DESIGN DEVELOPMENT AND THERAPY
(2022)
Article
Biology
Kevin J. Tu, Sanjit K. Roy, Zachery Keepers, Manas R. Gartia, Hem D. Shukla, Nrusingh C. Biswal
Summary: The study investigates the effectiveness and molecular characteristics of the combination therapy of Docetaxel (DXL) and radiation in vitro. The results suggest that DXL sensitizes castration-resistant prostate cancer (CRPC) cells to radiation by downregulating CAV-1.
INTERNATIONAL JOURNAL OF RADIATION BIOLOGY
(2023)
Article
Oncology
Chi-Shin Tseng, Jui-Han Yang, Shi-Wei Huang, Yu-Jen Wang, Chung-Hsin Chen, Yeong-Shiau Pu, Jason Chia-Hsien Cheng, Chao-Yuan Huang
Summary: This study aimed to investigate the survival outcomes of mCRPC patients receiving first-line ARATs and prognostic factors for patient survival. The results showed that mCRPC patients who had a PSA nadir <= 2 ng/mL or a TTN >= 7 months had better survival.
Article
Oncology
Wei Ning, Pengkang Chang, Ji Zheng, Fan He
Summary: This case report highlights the potential effectiveness and safety of a second docetaxel rechallenge as a later-line treatment strategy for patients with mCRPC who are concerned about the high costs of multigene molecular testing and PARP inhibitors, as well as repeated prostate needle biopsy.
FRONTIERS IN ONCOLOGY
(2023)
Article
Multidisciplinary Sciences
Atefeh Deris, Mahdi Sohrabi-Haghighat
Summary: Patients with mCRPC are classified into three groups based on their response to Abiraterone treatment: best responder, responder, and non-responder. Drug-resistant cells may hinder successful outcomes in the latter two groups. To overcome this challenge, a combination of Docetaxel and Abiraterone is proposed to control both the overall cancer cell population and the drug-resistant subpopulation. Evolutionary Game Theory (EGT) is used as a mathematical modeling approach to study the competition and evolution of mCRPC cancer phenotypes.
Article
Biochemistry & Molecular Biology
Karim Fizazi, Arun A. Azad, Nobuaki Matsubara, Joan Carles, Andre P. Fay, Ugo De Giorgi, Jae Young Joung, Peter C. C. Fong, Eric Voog, Robert J. Jones, Neal D. Shore, Curtis Dunshee, Stefanie Zschaebitz, Jan Oldenburg, Dingwei Ye, Xun Lin, Cynthia G. Healy, Nicola Di Santo, A. Douglas Laird, Fabian Zohren, Neeraj Agarwal
Summary: This study investigates the combination of the poly(ADP-ribose) polymerase inhibitor talazoparib with enzalutamide for the treatment of metastatic castration-resistant prostate cancer. The results show that the combination significantly improved radiographic progression-free survival in patients with specific gene alterations, suggesting it as a potential first-line treatment option.
Letter
Oncology
Antonella Ferro, Paolo Cristofolini, Carlos A. Garcia-Etienne, Orazio Caffo, Marco Pellegrini, Carmine Fanto, Salvatore Mussari, Monica Campregher, Giovanni Maria Guarrera
Article
Oncology
Palma Fedele, Antonella Ferro, Valeria Sanna, Nicla La Verde, Ida Paris, Rita Chiari
Summary: The COVID-19 pandemic has caused a sudden reorganization of healthcare structures and had consequences in cancer patients management. Italian oncologists have tried to ensure continuity of care for patients with metastatic breast cancer, with main changes including de-escalation of cancer treatments and greater use of oral anticancer drugs. Some subgroups of patients, especially the elderly and endocrine-responsive patients, have been undertreated during the COVID-19 pandemic.
JOURNAL OF CHEMOTHERAPY
(2021)
Review
Oncology
Antonello Veccia, Stefania Kinspergher, Mariachiara Dipasquale, Orazio Caffo
Summary: The brain is a common site of metastases in lung cancer patients, with treatment mainly focusing on immunotherapy and local treatments like radiotherapy, significantly improving patient survival.
Article
Oncology
Orazio Caffo, Viviana Frantellizzi, Fabio Monari, Andrea Sbrana, Renato Patrizio Costa, Carmine Pinto, Marcello Tucci, Sergio Baldari, Gaetano Facchini, Roberto Bortolus, Filippo Alongi, Pierpaolo Alongi, Antonio Palermo, Stefano Fanti, Elisa Biasco, Alessandra Murabito, Angelina Filice, Clizia Zichi, Salvatore Pignata, Eugenio Borsatti, Matteo Salgarello, Massimiliano Spada, Enrico Cortesi, Giuseppe De Vincentis
Summary: This study demonstrates the activity of RA223 regardless of treatment line, with patients completing all RA223 courses having significantly longer overall survival. Patient selection plays a crucial role in maximizing the activity of RA223.
Article
Oncology
Orazio Caffo, Cinzia Ortega, Franco Nole, Donatello Gasparro, Claudia Mucciarini, Michele Aieta, Vittorina Zagonel, Roberto Iacovelli, Ugo De Giorgi, Gaetano Facchini, Antonello Veccia, Erica Palesandro, Elena Verri, Sebastiano Buti, Giorgia Razzini, Giovanni Bozza, Marco Maruzzo, Chiara Ciccarese, Giuseppe Schepisi, Sabrina Rossetti, Francesca Maines, Stefania Kinspergher, Lucia Fratino, Paola Ermacora, Maurizio Nicodemo, Monica Giordano, Donata Sartori, Daniela Scapoli, Roberto Sabbatini, Giovanni Lo Re, Franco Morelli, Alessandro D'Angelo, Isabella Vittimberga, Paolo Lippe, Francesco Carrozza, Caterina Messina, Luca Galli, Francesca Valcamonico, Camillo Porta, Giovanni Pappagallo, Massimo Aglietta
Summary: The combination of enzalutamide and docetaxel appears to be more clinically beneficial than docetaxel alone in previously untreated mCRPC patients, although serious adverse events were more frequent. The results suggest that first-line treatment with this combination could lead to additional clinical benefit when prompt and prolonged disease control is needed. However, caution should be exercised due to the study's phase II design and the lack of overall survival benefit.
EUROPEAN JOURNAL OF CANCER
(2021)
Article
Immunology
Antonello Veccia, Vincenzo Sforza, Emanuela Vattemi, Alessandro Inno, Stefania Kinspergher, Mariachiara Dipasquale, Stefania Gori, Alessandro Morabito, Ileana Baldi, Orazio Caffo
Summary: The study found that higher LIPI scores were associated with worse survival rates in advanced non-small-cell lung cancer patients receiving first-line pembrolizumab treatment. However, LIPI does not represent a good prognostic survival model based on the c-statistic and area under the curve analysis.
Review
Oncology
Orazio Caffo, Marco Messina, Antonello Veccia, Stefania Kinspergher, Francesca Maines, Carlo Messina
Summary: Real-world data suggest a possible interplay between ADT and susceptibility to SARS-CoV-2 infection, but current evidence is conflicting. Larger and more precise studies are needed to determine the true effect of ADT in preventing or reducing the severity of SARS-CoV-2 infection.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2021)
Article
Health Care Sciences & Services
Alessandro Passardi, Flavia Foca, Orazio Caffo, Carlo Alberto Tondini, Alberto Zambelli, Roberto Vespignani, Giulia Bartolini, Francesco Giulio Sullo, Daniele Andreis, Marco Dianti, Claudio Eccher, Enrico Maria Piras, Stefano Forti
Summary: This study tested a platform called ONCO-TreC, which is designed to support home management of oral anticancer treatments and provide secure communication between patients and health care professionals. The results showed that the system has a high ability to measure adherence to treatment and is highly usable and acceptable. However, there is room for improvement in the system's reliability in recording toxicities.
JOURNAL OF MEDICAL INTERNET RESEARCH
(2022)
Article
Oncology
Roberta Coletti, Andrea Pugliese, Andrea Lunardi, Orazio Caffo, Luca Marchetti
Summary: This mathematical study investigates the clinical relevance of ipilimumab for the treatment of castration-resistant prostate cancer patients. The results suggest that high-dose short-term administration of ipilimumab may be more effective, and combining ipilimumab with sipuleucel-T can improve tumor control.
Review
Oncology
Carlo Cattrini, Orazio Caffo, Ugo De Giorgi, Alessia Mennitto, Alessandra Gennari, David Olmos, Elena Castro
Summary: This review discusses the use of apalutamide, darolutamide, and enzalutamide in patients with nmCRPC and the clinical implications of novel imaging techniques for treatment selection.
Review
Oncology
Alberto Lapini, Orazio Caffo, Giario Natale Conti, Giovanni Pappagallo, Marzia Del Re, Rolando Maria D'Angelillo, Ettore Domenico Capoluongo, Francesca Castiglione, Matteo Brunelli, Roberto Iacovelli, Ugo De Giorgi, Sergio Bracarda
Summary: The recent approval of PARP inhibitors for the treatment of metastatic castration-resistant prostate cancer (mCRPC) patients with BRCA mutations has brought the possibility of targeted treatment in this disease. However, this raises questions regarding the management of prostate cancer, including the timing and method of detecting BRCA mutations, therapeutic implications, and family screening. The Italian Society for Uro-Oncology (SIUrO) organized a Consensus Conference to develop suggestions for clinicians managing prostate cancer patients, involving major Italian scientific societies.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY
(2023)
Article
Oncology
Silke Gillessen, Giuseppe Procopio, Stefanie Hayoz, Eloise Kremer, Michael Schwitter, Orazio Caffo, David Lorente, Augusto Pedrazzini, Guilhem Roubaud, Soazig Nenan, Aurelius Omlin, Consuelo Buttigliero, Juan Ignacio Delgado Mingorance, Aranzazu Gonzalez-del-Alba, Maria Teresa Delgado, Franco Nole, Fabio Turco, Ricardo Pereira Mestre, Karin Ribi, Richard Cathomas
Summary: Darolutamide maintenance after successful taxane chemotherapy shows promising efficacy and safety in patients with metastatic castration-resistant prostate cancer (mCRPC).
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Giuseppe Luigi Banna, Umberto Basso, Emilio Francesco Giunta, Lucia Fratino, Sara Elena Rebuzzi, Sebastiano Buti, Marco Maruzzo, Ugo De Giorgi, Veronica Murianni, Marika Cinausero, Helga Lipari, Teresa Gamba, Orazio Caffo, Davide Bimbatti, Arianna Dri, Alessandra Mosca, Paola Ermacora, Francesca Vignani, Aichi Msaki, Barbara Bonifacio, Valentina Lombardo, Vincenza Conteduca, Giuseppe Fornarini, Pasquale Rescigno
Summary: This study investigated prognostic factors for older patients with metastatic castrate-resistant prostate cancer (mCRPC) receiving androgen receptor pathway inhibitors (ARPIs) treatment. It found that G8 assessment score <= 14 and PSA decline >= 50% were independent factors associated with worse radiographic progression-free survival and overall survival.
Letter
Oncology
Orazio Caffo, Massimo Di Maio
EUROPEAN UROLOGY ONCOLOGY
(2021)
Article
Oncology
Orazio Caffo, Donatello Gasparro, Giuseppe Di Lorenzo, Alberto Dalla Volta, Pamela Guglielmini, Paolo Zucali, Roberto Bortolus, Alessia Cavo, Giovanni Ceresoli, Rita Chiari, Giuseppe Fornarini, Lucia Fratino, Alessandro Iaculli, Marco Maruzzo, Cristina Masini, Franco Morelli, Claudia Mucciarini, Giuseppe Procopio, Roberto Sabbatini, Elena Verri, Stefania Kinspergher, Francesca Maines, Carlo Messina, Antonello Veccia, Maddalena Donini
EUROPEAN JOURNAL OF CANCER
(2020)